Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — Investor Day (June 2023)
70 slides from Sab Biotherapeutics's investor day presentation, Jun 14, 2023
Slide 1: SAB Biotherapeutics R&D Day
Wen BIOTHERAPEUTICS DISEASE SPECIFIC HUMAN IMMUNOGLOBULIN (hlgG) DERIVED FROM TC BOVINES SAB BIOTHERAPEUTICS R&D DAY | June 14, 2023 Eddie J. Sullivan, PhD President and CEO NASDAQ: SABS (© 2005 SAB BIOTHERAFEUTICS\ING.
Slide 2: Forward-Looking Statements
Forward-Looking Statements 4. BIOTHERAPEUTICS Thermeteria inthis presentation hasbeen prepared by SAB Biotherapeutics, ine. (SAB"] ane general backgiound information about SAB’s activities cuttent as ofthe date of thispresentation. This information is ghwen in surnmary form and isnotintended to he c
Slide 3: Investment Thesis
Investment Thesis 4. 'SAb v BIOTHERAPEUTICS SAB Biotherapeuticsis a next generation antibody platform company with human data in > 700 patients across three indications, currently focused on prevention of Type 1 diabetes. MoA of SAB-142 in T1D is a proven therapeutic approach with support and enthus
Slide 4: Human Immunoglobulin G Produced in Transchromosomic Bovine
Human Immunoglobulin G Produced in Transchromosomic Bovine Wen, BIOTHERAPEUTICS Tc Bovine” contain all the human immunoglobulin genes Tc Bovine™ + Only transgenic animal that carries the entire human immunoglobulin (|g) heavy and light (1) chain loci, + HAC is subject to mitosis along with the other
Slide 5: Human Anti-Thymocyte Globulin (hATG) - Focused Program Development in Type 1 Diabetes
ay er PSAb / BIOTHERAPEUTICS Human Anti-Thymocyte Globulin (hATG) - Focused Program Development in Type 1 Diabetes (© 2023 SAB BIOTHERAPEUTICS, INC.
Slide 6: What is Type 1 Diabetes?
What is Type 1 Diabetes? (©2003 Se BIOTHERAPEUTICS INC. conn BIOTHERAPEUTICS Q Type Diabetes isan autoimmune disorder caused by destruction of insulin producing beta- cells in the pancreas from the patient's own immune system O Anyone can get it, but it is most often diagnosed in young children with
Slide 7: Type 1 Diabetes: For Millions, a Daily Disease for a Lifetime
Type 1 Diabetes: For Millions, a Daily Disease for a Lifetime There is no cure, only continuous management eas PRSAb Physical Reminders AOE \ Restrictons} & \ (© 2003 Ste BIOTHERAPEUTICS, INC. BIOTHERAPEUTICS
Slide 8: The Promise of SAB-142: Durable Disease Modification
The Promise of SAB-142: Durable Disease Modification 2b Modifying vs Managing TID would be life changing BIOTHERAPEUTICS SAB-142 could be uniquely positioned to support patients across the T1D landscape Delay Onset Halt Progression Prevent Disease AHeathier Childhood Less Severe Preserve Insulin Con
Slide 9: Disease Modification is Just Beginning
Disease Modification is Just Beginning SAB-142: Fully-human profile has the potential to advance Standard of Care eas PRSAb BIOTHERAPEUTICS Stage 2 Prevention Market Stage 3 Recent Onset Market vale Projected to reach>$1B in ww Tzield sales! by 2028 (teplizumab-manv) In the US, only family relatives
Slide 10: SAB-142 Development Plan and Catalysts
SAB-142 Development Plan and Catalysts Phase 1 First Phase 2 Phase 2 a Top-Line Readout Top-Line == ti 2023 2028 2025 2026 Phase 1 Study: Cohorts 1-4 Phase 1 Clinical Phase 1 Top Line Results Phase 2 Phase 2 Study POC/ORF Regulatory © CTA Approved/CTN Acknowledged cmc Development (EEE FG to enable P
Slide 11: Tc Bovine Derived Infectious Disease Targeted hIgG Out-Licensing Opportunities
Yen BIOTHERAPEUTICS Tc Bovine Derived INFECTIOUS Disease Targeted higG Out-Licensing Opportunities (© 2023 SAB BIOTHERAPEUTICS, INC.
Slide 12: SAB Platform has Broad Potential Therapeutic Applications
SAB Platform has Broad Potential Therapeutic Applications 4. The Company is currently focusing its resources on the Type 1 Diabetes SAB-142. program; SAB is actively SIOTHERAREUTIGS engaging in partnership for further development of other pipeline programs PIPELINE PRobUCT INDICATION DISCOVERY PRECL
Slide 13: Value Proposition: SAB-176
Value Proposition: SAB-176 PRSAb BIOTHERAPEUTICS | First-in-class fully-human immunoglobulin treatment aimed to provide superior long-lasting efficacy for prophylaxis and management of influenza in high-risk patients Key Differentiators Pe First and only broadly neutralizing immunoglobulin for proph
Slide 14: SAB-185 Potential Value to Patients
SAB-185 Potential Value to Patients 4 Pecan _ ‘Only biologic with sustained efficacy across non-Omicron and Omicron variants in high-risk rics, and low-risk patients Only antibody treatment designed to reduce risk of losing efficacy to escape mutants for COVID-19 patients ferentiators igh-risk Only
Slide 15: Value Proposition: SAB-195
Value Proposition: SAB-195 PXSAI BIOTHERAPEUTICS First-in-class fully-human immunoglobulin treatment with dual mechanism of action designed to treat severe CDI and reduce CDI recurrence in high-risk patients First-in-class fully human Only treatment with dual SAB-195 is atarget- immunoglobulin mode
Slide 16: SAB-176 & SAB-185 Designations
SAB-176 & SAB-185 Designations 4. 'SAb FDA has reviewed our platform on multiple occasions BIOTHERAPEUTICS + Breakthrough Therapy Designation (BTD) and Fast Track designation granted to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in
Slide 17: Intellectual Property
Intellectual Property Regulatory Exclusivity VefrenceModact Las ity (0 prevents cesar of aULA “or Boss SAB 7602040 + Orne PAD) > Reference oduct Belusvry (BE) prevents ensure of 36. for sila SAB-CA(2941 GNF —————SSD Fofrence Posh lity BFE prevents kero 9814 fo isi SAB 142 (26 1 m0 26D) ee Patent Exc
Slide 18: Today's Presenters
Today's Presenters Eddie J. Sullivan, PRD PRESIDENT & CEO CO-FOUNDER 1 rye biotech + Former Japanese pharma El + B10 Executive Commitee 1 Reproetive prysingit ‘Alexandra Kropotova, MD EVP CHEF MEDICAL OFFER 1 zor yats global inital devdopment + Siopharmaceutial RAD led, Pz, yeh, Sof, Te Spey RED + B
Slide 19: Validated Tc Bovine Platform to Address Complex Immune and Autoimmune Diseases
Yew BIOTHERAPEUTICS VALIDATED TC BOVINE™ PLATFORM TO ADDRESS COMPLEX IMMUNE AND AUTOIMMUNE DISEASES SAB BIOTHERAPEUTICS R&D DAY| June 14, 2023 Christoph Bausch, PaD EVP & Chief Operating Officer NASDAQ: SABS © 2023 SAB BIOTHERAPEUTICS, INC.
Slide 20: A Powerful Technology to Produce Fully Human IgG Polyclonal Antibodies
20 A Powerful Technology to Produce Fully Human IgG Polyclonal Antibodies Te Bovine™ contain all the human immunoglobulin genes Telomere eK hchr 2 Human artificial chromosome (HAC) ~17Mb contains the entire unarranged VDJ human immunoglobulin loci (IgH + Igk) antramen: IH hchr 14 Telomere a8 BIOTHE
Slide 21: Validated Platform For Producing Fully Human IgG Therapeutics
a Validated Platform For Producing Fully Human IgG Therapeutics First of its kind Tc Bovine” platform clinically validated with several programs advancing through clinical development PROPRIETARY y Anmicen (Ss FORMULATION TYPE a & Dag - Petit yx. : fais R. SAB-adj-1 Purtiedbacterial proteinantigens
Slide 22: High Titers and Avidity (Potency): Driven By Hyperimmunization
High Titers and Avidity (Potency): Driven By Hyperimmunization Titers and avidity increases with each immunization Neutralizing Titers Hyperimmunization Be Sd pe TeBovine™ i Vaccination 7 1 WEEK — Vi V2 VB V4 VB Avidity 0.0001; v3 0.001 ie io WE 0.01 Bc V5 Trget Target’ Toga wn PRSAb BIOTHERAPEUTICS
Slide 23: SAB Human Immunoglobulin: Next Generation of Biologics
SAB Human Immunoglobulin: Next Generation of Biologics Key Product Differentiators. vs Monoclonal Antibodies: Multi-target capability in a single therapeutic ¥ Natural multi-epitope targeted higG selected and produced 7 vivo ¥ Abilityto target multipledisease pathways atonce increase potential for s
Slide 24: Anti-Idiotype: Proof of Principle to Treat Autoimmune Disease
Anti-ldiotype (ID ): Proof of Principle to Treat Autoimmune Disease Multi-target capabilityin a single therapeutic Ability to target multiple autoantibodies at once increase potential for superior efficacy J Known mAb autoantibodies were selected and used as antigens for hyperimmunization IgGlisotyp
Slide 25: Tc Bovine Anti-Variable/Anti-ID IgG are Specific to the Variable Region
Tc Bovine™ Anti-Variable/Anti-ID IgG are Specific to the Variable Region 75 Data indicates distinct polyclonal antibody responses to 2 different anti-idiotype targets(antigens)in the same Tc Bovine. 100X Excess Competitive Ab/Fragments 4 mAbG4-like Fab Fragment mAbGL Te bovine coment: {TcBovine Anti
Slide 26: SAB-142 Product Characterization and Scaled Production
aie ef PSAb ; BIOTHERAPEUTICS SAB-142 (Human Anti-Thymocyte Globulin) Product Characterization and Scaled Production (© 2005 SAB BIOTHERAFEUTICS, INC.
Slide 27: SAB-142 Potential for Best-in-Class Safety Profile with Higher Potency
SAB-142 Has Potential for a Best-in-Class Safety Profile with Higher Potency Compared to FDA Approved Rabbit ATG (Thymoglobulin) Better Safety Profile Red Blood Cell Binding wn Higher Potency TILI||| complement-cependent cytotoxicity (CDC) Sample Activity (ug/ml) Sample Mean ECs0 SD (ug/mL) Fei ci 2
Slide 28: SAB-142 Targets Lymphocytes (CD2) Similar to rATG
SAB-142 Targets Lymphocytes (CD2) Similar to rATG Multi-Target Binding of Thymoglobulin (rATG) IgG Targets CD2 Polyclonal Antibodies Anti-CD2 Activity Sample Mean ECso #$D (g/mL) fs Sad Y Lymphocytes T-Lymphocytes HelperT-Cells Cytotoxic T-Cells aie 0.19 + 0.009 Thymoglobulin includes antibodies aga
Slide 29: SAB-142 Demonstrates Similar T-Cell Subset Binding Profile as rATG
SAB-142 Demonstrates Similar T-Cell Subset Binding Profile as rATG 2 Targets T-cells (CD3*), T-Helper Cells(CD4"), and T-Killer Cells(CD8*) similar to rATG suggesting similar muti-target binding cD4* "| : — : ne ical T-Lymphocytes (© 2025 SAB BIOTHERAFEUTICS, INC. Helper T-Cells @n Cytotoxic T-Cells
Slide 30: SAB-142 Demonstrates Similar T-Cell Subset Mechanism of Action as rATG
SAB-142 Demonstrates Similar T-Cell Subset Mechanism of Action as rATG \. Similar to rATG, exposure to SAB-142 results in the reduction of cytotoxic CD8* T-cells, protection of Tregs, and conversion of naive CD4* to an activated state suggesting similar MoA as rATG as a treatment for TID CD8T Cells
Slide 31: SAB-142 Production Similar to FDA Approved rATG
SAB-142 Production Similar to FDA Approved rATG a-¥- 2-8 Tiymogiobulin_ Ant-thymogye Globulin (Rabbi) stn Irma ti Ay Proton Pasa calc © rom ce) ‘oe *~ it § SAB-142 Anti-Thymocyte ene —= Globulin (Human) scone ©2008 SAB BIOTHERAPEUTICS. INC. Pete oot Ati it it PRSAb BIOTHERAPEUTICS
Slide 32: Demonstrated Process Scalability & Manufacturing Capabilities
Demonstrated Process Scalability & Manufacturing Capabilities EMERGENT ee Early Clinical MFG rocess Development ili - ean ea Commercial MFG Guality Control and vom: paceriin Quality Assurance vacua eae OL vcaPsa uly Compl Supporti suse oe: a isharea erin ero 800 & 2300 A us us ve: Antigen developmen
Slide 33: SAB-142 is Manufacturing Clinical Material and Positioned to Scale
SAB-142 is Manufacturing Clinical Material and Positioned to Scale to Commercial Production it @ Current SaB-142 Plasma inventory sufficient to produce clinical t material to support global phase 1-2 clinical trials f @ Tc Bovine” Platform is immediately scalable to support 1 op t 142 commercial pro
Slide 34: Advancing a Powerful New Class of Therapeutic Immunoglobulins
Wen BIOTHERAPEUTICS ADVANCING A POWERFUL NEW CLASS OF THERAPEUTIC IMMUNOGLOBULINS (higG) SAB BIOTHERAPEUTICS R&D DAY | June 14, 2023 Alexandra Kropotova, MD EVP & Chief Medical Officer NASDAQ: SABS (© 2005 SAB BIOTHERAFEUTICS\ING.
Slide 35: Proven Clinical Regulatory Path for IgG Polyclonal Antibody Products
35 Proven Clinical Regulatory Path for IgG Polyclonal Antibody Products 40+ FDA Approved through the Center for Biologics Evaluation and Research(CBER) it a or reat AnimalPolelonal Antibodies Human Polyclonal Antibodies (oninat-derbed mine glean presets) (hua dered mane lb products) IgcaPolyetonat ‘
Slide 36: The Global Diabetes Crisis Few are Talking About
The Global Diabetes Crisis Few are Talking About + — Since 2000, T1D prevalence has increased at four times the rate of global population growth? + Anestimated 8.4 million people were living with Type 1 Diabetes across the globe in 2021? + This number is predicted to increase to 13.5-17.4 million pe
Slide 37: Living with Type 1 Diabetes: for Millions, a Daily Disease for a Lifetime
a Living with Type 1 Diabetes: for Millions, a Daily Disease for a Lifetime Thereis no cure, only management Signs and Symptoms Complications Diabetes Management Increases thirst & - urination Hyperglycemia management : Hypoglycemia Fatigue & weakness “management = Diabetes complications High glucos
Slide 38: Anti-Thymocyte Globulin (rATG) Demonstrates Strong Disease-Modifying Efficacy In T1D
Anti-Thymocyte Globulin (rATG) Demonstrates Strong Disease-Modifying Efficacy In T1D ‘Anti-Thymocyte Globulin Polyclonal Abthat restrains the immune system by targeting T-lymphocytes RabbitATG isa marketed products indicated fororgan transplantand aplastic, anemia Includes antibodies against T cell
Slide 39: Low-Dose Anti-Thymocyte Globulin (ATG) in Type 1 Diabetes: The Potential of SAB 142
Low-Dose Anti-Thymocyte Globulin (ATG) in Type 1 Diabetes: The Potential of SAB 142 June 2023 Michael J. Haller, MD Pg I Professor and Chief UFHealth Pediatric Endocrinology Shands children’s Hospital University of Florida
Slide 40: Disclosure
Disclosure | serve on the Scientific Advisory Board for SAb Biotherapeutics | have received company stock options for that role
Slide 41: Type 1 Diabetes Pathogenesis
Type 1 Diabetes Pathogenesis ritatng _Gentepredineton bly cewnismihtocr | |” teleycierorinageto inate immu abersies (Prgitatng event) 3nd peat, ‘5 Ps oftneormeret rane ight inne ‘utantbe ight epee teteratyehitry syptomatctyel dates ‘coeetaetie nang cr sins lob opexte spimomatcorset overt ‘mali abocr
Slide 42: What is the scope of the problem?
What is the scope of the problem? © Type 1 diabetes - 1 in 300 children © 1in7 health care dollars o Tcell mediated.... but highly heterogeneous © Likely ideal for polyclonal Ab / multiple targets o Need induction and maintenance therapies
Slide 43: "Thick brown muck" lowered glucose
“Thick brown muck” lowered glucose from 520 to 120 mg/dl 7.5ml into each buttock
Slide 44: 100+ years Later.. Still Insulin
100+ years Later.. Still Insulin
Slide 45: Tzield / Teplizumab - Approved
Tzeild / Teplizumab - Approved 1992 to November 17, 2022 .... 30+ year effort Nal ead So USA Tah. may 9 MONOCLONAL Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice — Ng wart Cueoun En Tae, QUE Pe, Fen Baca y Naa de Sa de Rc Mie, pa May, 1 Re Ss, 98 Po, Fa
Slide 46: Monoclonals are great but what about Polyclonals?
Monoclonals are great but what about Polyclonals? HU class | \ Thymogoblin heavy chain cos COita HULDR * A a it y cove £2 mioro-globulin coy 045 of P 025 Y te ons x \ 03
Slide 47: Thymoglobulin
Thymoglobulin o Human Thymus / T-cells > Immunized Rabbit o Polyclonal Mix of Rabbit Anti-Human Antibodies oFDA approved ~30 years o Standard in Renal Transplant - up to LOmg/kg oNear complete depletion of Treg and Teff with slow recovery at Transplantdose —_iyrogobuin’ Aatthymog Gul bi) o What abou
Slide 48: "High" Dose ATG in T1D (6.5mg/kg)
“High” Dose ATG in T1D (6.5mg/kg) o ho Ss 5s Ss om -» bw C-peptide AUC change from baseline (pmol/ml) Time (months) Gitelman et al. Diabetologia 2016; 59(6)
Slide 49: High Dose ATG (6.5mg/kg)
High Dose ATG (6.5mg/kg) Too much Treg Depletion? a b = (Mo e 3 2 ™ 4 i : é é — f 5 3 0 ose 2 8 Om ‘Time (months) c qd. ; ee : are 3 38 40 : He i Be 00 oie 2 8 mW ‘Time (months) 100% Cytokine Release 100% Serum Sickness Gitelman et al. Diabetologia 2016; 59(6)
Slide 50: Low-Dose ATG in New Onset T1D
Low-Dose ATG in New Onset T1D NIH TrialNet C-Peptide AUC Mean Over Time By Treatment Group 42 © ~——— Placebo - Mean & 95% Cl ° ATG Only - Mean & 95% Cl 205 C-Peptide AUC 9 12 18 4 Time on Study (months) Halleret al. Diabetes. 2019. Jun,68(6)-1267-1276
Slide 51: Outcomes of ATG in New Onset T1D
Outcomes of ATG in New Onset T1 Age Regimen Primary Outcome: {yrs (AUC C-pepti ATG- Low 89 12-45 2.5mg/kglV over 2 days 2hr MMTT at 0.00005 Dose 2 years ATG-High 52 12-35 6.5mg/kglV over 4 days 2hrMMTT at 0.591 Dose (START) year Low dose - 35% CRS / 71% Serum Sickness High dose -100% CRS / 100% Seru
Slide 52: Low-Dose ATG: Predicting Responders
Low-Dose AT! Predicting Responders Population Intervention @eceeee | 1 00 9 0 __o __o ATG nooo oo Ht ATGIGCSE $ 12:45 years os with Meese ae = S event onset Type 1 Diabetes festa Baseline Predictors Posttreatment af Response Ps atonesmndes Pasir esponse ‘th q “= @ 4 seenne "oN : oxo | 8 3 sy \ were
Slide 53: Low-Dose ATG - Lymphocyte Recovery
Low-Dose AIG - Lymphocyte Recovery Above Clinical Threshold Lymphocytes_ABS Responder at + NotResponder 5 reser a 3 Treamentam mt — Pucibo — ne — nrecese 0 e esa == Lymphooyte absolute value reference pee range (1.00 - 3.20 x 10° cells/tL) lina Tesh ‘ina = = moose Jacobsen et al. /C/-!Under Revision
Slide 54: Low-Dose ATG - Absolute CD4 and CD8
Low-Dose ATG - Absolute CD4 and CD8 = rarest: Clinical Threshold Jacobsen et al. /C/-!Under Revision
Slide 55: Low-Dose ATG - Treg / CD4 Preservation Relative to High Dose
Low-Dose ATG - Treg / CD4 Preservation Relative to High Dose oHigh Dose ATG Trial: CD4, CD8, and Tregs J, 0 Slow to recover, some lymphocytes counts still 0< 1000 cells/uL at 12 months oLow-dose ATG trial: CD4 J. 0 CD4 Tconv depletion and increased effector memory 0 CD8T cells increased with higher
Slide 56: Cross Trial Comparison
Cross Trial Comparison - 2 Years 2 Yea Treatment Goup Means fom 6 Seleied Studies Adjusts for Bassline Cpepie& Age (Study Etec Rtaned) 79 Yow ie a ee) ee ae . Effect of Low-dose 3 ATG superiorat i [ 2years to even iar ; i | Teplizumab 2 fo ¢ 8 Trane Gow | wl fe em cet ee er 4 elem 9 Roo oe > st note
Slide 57: Low Dose ATG Prevention Study
Low Dose ATG Prevention Study 0 Stage 2 T1D = Multiple Ab+ / Dysglycemic o Age 12andup © Single course low-dose ATG (2.5mg/kg) 0 2/Vinfusions on back-to-back days o 1:1 Randomization 144 Subjects Type! : ! Diabetes Trial
Slide 58: A Polyclonal ATG (SAB-142)?
AB Polyclonal ATG (SAB-142) ? © Eliminate Serum Sickness O Re-treatment without risk © Could entirely replace current polyclonal immunosuppressive (Thymoglobulin) if similarly effective © Kidney Transplant / Autoimmune Disease / Cancer Therapy © Large untapped market
Slide 59: What SAB-142 could offer…
Slide 60: Acknowledgements
Acknowledgements Typel al THE LEONA M. AND HARRY B. Traine? — HELMSLEY National Institute of Diabetes and Digestive and Kidney Diseases a pea pe enn rity JDRFz Imes
Slide 61: SAB-142: Fully Human Anti-Thymocyte Globulin for Delaying Onset/Progression of T1D
Yew BIOTHERAPEUTICS SAB-142: FULLY HUMAN ANTI-THYMOCYTE GLOBULIN FOR DELAYING THE ONSET AND/OR PROGRESSION OF TYPE 1 DIABETES(T1D) SAB BIOTHERAPEUTICS R&D DAY | June 14, 2023 Alexandra Kropotova, MD EVP & Chief Medical Officer NASDAQ: SABS (© 2005 SAB BIOTHERAFEUTICS\ING.
Slide 62: SAB-142 has Strong Potential to Control or Prevent T1D Over the Entire Life Span
SAB-142 has Strong Potential to Control or Prevent 11D 2 Over the Entire Life Span 2. BIOTHERAPEUTICS Indication 2: Stage 2T1D delay of onset — Indication 1: Genetic Risk Stage 3T1D delay of progression Indication 3: x Immune Maintenance of Stage 3 or Activation >. complete delay of onset Starting P
Slide 63: SAB-142 has Similar MoA to rATG with Distinct Advantages
SAB-142 has Similar MoA to rATG with Distinct Advantages @ Rich & Fully Human Antibody Diversity VDu repertoire usage mimics human- derived diversity in variable region Tee0wNen Hun CONTROLS. HUNAN LUPUS TICS IN, sta on fe @ Identical In Vitro Binding SAB-142 vs. Rabbit THYMO-AF488 se 8 SAB-142 Anti
Slide 64: SAB-142 In Vivo Proof of Principle
SAB-142 In Vivo Proof of Principle Demonstrated impact on major relevant T-cell subsets TID Pathophysiology! ‘Autonoigens for an insulin producing beta cells ad cvulatein the Blood steam and Processing ac presentation of autoantigen by antigen-presenting cells Activation of Helper Lymphocytes etivai
Slide 65: SAB-142 Has a Similar MoA to rATG with Several Distinct Safety Advantages
SAB-142 Has a Similar MoA to rATG with Several Distinct Safety Advantages Majority of patients, develop grade3 serum sickness Lower half-lifeand inabilityto re-dose dueto anti-drug antibodies (© 2023 SAB BIOTHERAPEUTICS. INC. Wenn SIOTHERAPEUTICS No serum sickness expected due to fully human product
Slide 66: Long-Term Safety of Low-Dose rATG in T1D Patients
Long-Term Safety of Low-Dose rATG in T1D Patients Single course of low dose rATG has shown adequate safety in the up to 5+ years of followup PS ap BIOTHERAPEUTICS Randomized, PBO-controlled , ‘ Hi i Se Sicki & trials in TID patients Infections hence stale shad eves, | camels ° @ ° ct rae Tee ee | +
Slide 67: SAB-142 vs Teplizumab
SAB-142 vs Teplizumab a1 Projected favorable risk/benefit profile compared to other treatments BIOTHERAPEUTICS | Teplizumab (Tzield) ‘SAB-142 Humanized mAB Human pAbs Multifectorial: ModsofAction Be De Shown to bind to similarcell lineagesasrATS Indications Stage 2 (Q1 2023) Targeting Stage? & Stage
Slide 68: SAB-142: Clinical Development Plan in T1D
cy SAB-142: Clinical Development Plan in T1D 4. BIOTHERAPEUTICS “Fully HUman anti-thymocyte biologic in first-in- MAN clinical study (HUMAN trial)” Phase 1: First in Human, Randomized, Single Ascending Dose trial SAB-142 dose range: 0.01mg/kg up to 2.5mg/kg STUDY DESIGN Primary end point: Acute (ser
Slide 69: SAB-142 Key Milestones
SAB-142 Key Milestones First Phase 2 Phase 2 Readout Top-line FPL ke)» aa 2023 2024 2025 2026 Phase 1 Top Line Results’ hase 2 SSN REST QEEEDGES MIG to enable Phase 1 cmc Development Phase 1 (EEE MIG to enable Phase 2 = ret paver Pac: Poe of concert Dees Docefange Fndingsuiy CTA Cine Tal Applecton C
Slide 70: Summary
Summary SAB-142: First-in-classfully-human multi-target antibody treatment aimed to provide superior safety and efficacy for delaying onset or progression of Type 1 Diabetes. MoA of SAB-142 in TLD is clinically- validated in numerous clinical trials with rabbit ATG Safety database with human datain